2009
DOI: 10.1158/0008-5472.sabcs-3063
|View full text |Cite
|
Sign up to set email alerts
|

Synthetic lethality when combining phosphoinositide 3-kinase alpha and beta catalytic subunit-directed RNAi and estrogen deprivation for estrogen receptor positive breast cancer: implications for clinical trial design with pharmacological inhibitors.

Abstract: #3063 Background: Endocrine therapy with estrogen deprivation (ED) induces cell cycle arrest in sensitive estrogen receptor positive (ER+) breast cancers, but typically not apoptosis, thus relapse is common despite ED due to residual surviving tumor cells. The phosphoinositide 3-kinase (PI3K) pathway, which promotes cell survival, is hyperactivated in ER+ breast cancer due to mutations of genes in the PI3K signaling cascade, most commonly PIK3CA. We therefore investigated the role of p110α and p… Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles